MBX Biosciences, Inc. (MBX)

Compare

6.37

-0.60

(-8.61%)

At close: April 3 at 4:00:01 PM EDT

6.90

+0.53

+(8.32%)

Pre-Market: 5:45:53 AM EDT

MBX Biosciences to Participate in the 24th Annual Needham Virtual Healthcare Conference

CARMEL, Ind., March 26, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, will present at and participate in the 24th Annual Needham Virtual Healthcare Conference. 24th Annual Needham Virtual Healthcare Conference Date: Monday, April 7,

GlobeNewswire 9 days ago

MBX
-8.61%
MBX Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights

Enrollment complete in Phase 2 Avail™ trial of canvuparatide in hypoparathyroidism; topline results on track for Q3 2025 MBX 1416 Phase 2 trial in patients with post-bariatric hypoglycemia expected to begin in 2H 2025 Investigational New Drug submission anticipated in Q2 2025 for MBX 4291 in obesity $262.1 million in cash, cash equivalents and marketable securities as of December 31, 2024; expected to support operations into mid-2027 CARMEL, Ind., March 17, 2025 (GLOBE NEWSWIRE) -- MBX Bioscienc

GlobeNewswire 18 days ago

MBX
-8.61%
Insider Buyers At MBX Biosciences Likely Disappointed With 17% Slide

The recent price decline of 17% in MBX Biosciences, Inc.'s ( NASDAQ:MBX ) stock may have disappointed insiders who...

Simply Wall St. 22 days ago

MBX
-8.61%
MBX Biosciences Announces Additions to Leadership Team

Chatan Charan, Ph.D. appointed as Senior Vice President, Pharmaceutical Development and CMC Mark Hope appointed as Senior Vice President, Regulatory and Quality CARMEL, Ind., March 05, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the appointments of Chatan Charan, Ph.D. as Senior Vice Pres

GlobeNewswire 29 days ago

MBX
-8.61%
MBX Biosciences Completes Enrollment in Phase 2 Avail™ Trial of MBX 2109 (Canvuparatide) for Hypoparathyroidism

AvailTM trial exceeded enrollment target; topline results expected in Q3 2025CARMEL, Ind., March 03, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the completion of enrollment in its Phase 2 Avail™ trial of MBX 2109 (canvuparatide), the Company’s parathyroid hormone (PTH) peptide prodrug. C

GlobeNewswire last month

MBX
-8.61%
MBX Biosciences to Participate in March Investor Conferences

CARMEL, Ind., Feb. 18, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, will present at and participate in the following investor conferences: TD Cowen 45th Annual Healthcare Conference Date: Monday, March 3, 2025Format: Podium Present

GlobeNewswire last month

MBX
-8.61%
MBX Biosciences to Participate in Upcoming February Investor Conferences

CARMEL, Ind., Jan. 23, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, will present at, and participate in, the following upcoming investor conferences: Guggenheim SMID Cap Biotechnology Conference Date: Wednesday, February 5, 2025For

GlobeNewswire 2 months ago

MBX
-8.61%
MBX Biosciences' Investigational Drug For Weight Loss Surgery-Related Low Blood Sugar Shows Encouraging Action

On Tuesday, MBX Biosciences Inc. (NASDAQ:MBX) revealed results from its Phase 1 single ascending dose and multiple ascending dose trial of MBX 1416 in healthy adult volunteers. MBX 1416 is the company’s investigational long-acting glucagon-like peptide 1 (GLP-1) receptor antagonist, being developed for Post-Bariatric Hypoglycemia (PBH). PBH is a common and potentially serious complication that can occur after certain types of weight loss surgery. Trial data: MBX 1416 was generally well-tolerated

Benzinga 2 months ago

MBX
-8.61%
MBX Biosciences Announces Positive Phase 1 Topline Results for MBX 1416 for the Treatment of Post-bariatric Hypoglycemia

Phase 1 results support proceeding to Phase 2 in patients with post-bariatric hypoglycemia (PBH), which is expected to begin in 2H 2025 Phase 1 trial in healthy volunteers showed MBX 1416 was generally well-tolerated with a favorable safety profile Pharmacokinetic results demonstrated sustained dose-dependent exposure and support once-weekly dosing Company to host conference call to discuss results today at 8:30 am ET CARMEL, Ind., Jan. 07, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq:

GlobeNewswire 2 months ago

MBX
-8.61%
MBX Biosciences to Participate in 43rd Annual J.P. Morgan Healthcare Conference

CARMEL, Ind., Dec. 18, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14th, 2025, at 2:15 p.m. Pacific Time. The Company will also participate in 1

GlobeNewswire 3 months ago

MBX
-8.61%
MBX Biosciences Announces MBX 2109 Phase 1 Study Results Published in The Journal of Clinical Endocrinology and Metabolism

Peer-reviewed publication features positive results from multiple ascending dose (MAD) portion of Phase 1 MBX 2109 study in healthy participantsCARMEL, Ind., Dec. 02, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the publication of a peer-reviewed article highlighting results from the Phase

GlobeNewswire 3 months ago

MBX
-8.61%
MBX Biosciences Announces Last Subject Last Visit in Phase 1 Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia

Topline results expected in early January 2025CARMEL, Ind., Nov. 18, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the completion of the last subject’s last visit in its Phase 1 single and multiple ascending dose trial of MBX 1416, the Company’s long-acting glucagon-like peptide 1 (GLP-1) r

GlobeNewswire 4 months ago

MBX
-8.61%
MBX Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update

Total gross proceeds from upsized initial public offering and Series C financing were approximately $251.2 million Last subject last visit in Phase 1 trial of MBX 1416 anticipated by late November; topline results to be reported in early January 2025 Enrollment of Phase 2 Avail™ trial of MBX 2109 in hypoparathyroidism on track to complete in Q1 2025; topline results anticipated in Q3 2025 Strong cash position, with $277.1 million expected to support operations into mid-2027 CARMEL, Ind., Nov. 07

GlobeNewswire 4 months ago

MBX
-8.61%
MBX Biosciences to Participate in Upcoming November Investor Conferences

CARMEL, Ind., Oct. 28, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that its management team will participate in the following upcoming investor conferences: Guggenheim Inaugural Healthcare Innovation Conference Date: Tuesday, November 12, 2024Format: Fireside chatTime: 3:30 p.m. ESTLocati

GlobeNewswire 5 months ago

MBX
-8.61%
Opening Day: Another trio of biotech IPOs make Friday debut

The Partners Group-backed KinderCare sold 24 million shares for $24 each this Tuesday. At the IPO price, the childhood education company had a market value of $2.74B, based on the outstanding shares. Sky Quarry, Click Holdings, and SKK Holdings also opened for trading this week. Meanwhile, a new trio of biotech companies’ shares came to market on Friday as Upstream Bio, Ceribell and Camp4 Therapeutics each made their public debut. In mid-September, Bicara Therapeutics (BCAX), MBX Biosciences (MB

TipRanks 5 months ago

C

CBLL

ZBIO
-7.47%
MBX Biosciences Presents MBX 2109 Phase 2 Avail™ Hypoparathyroidism Trial Rationale and Design at the ASBMR 2024 Annual Meeting

CARMEL, Ind., Sept. 30, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that both the rationale and design of the Phase 2 Avail™ trial of MBX 2109, the Company’s potential long-acting parathyroid hormone (PTH) peptide prodrug, in adults with hypoparathyroidism (HP) were featured in a poster p

GlobeNewswire 6 months ago

MBX
-8.61%
OrbiMed Advisors LLC Acquires New Stake in MBX Biosciences Inc

On September 16, 2024, OrbiMed Advisors LLC, a prominent investment firm, marked a significant transaction by acquiring 3,812,215 shares of MBX Biosciences Inc (NASDAQ:MBX). This purchase, executed at a price of $16 per share, represents a new holding for the firm, reflecting a strategic move into the biopharmaceutical sector. The acquisition not only underscores OrbiMed's confidence in MBX Biosciences but also impacts its portfolio with a 1.19% position, highlighting the transaction's substantial scale and potential influence.

GuruFocus.com 6 months ago

MBX
-8.61%
MBX Biosciences Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

CARMEL, Ind., Sept. 16, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX) (“MBX Biosciences”), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the closing of its previously announced upsized initial public offering of 11,730,000 of its common stock at a price to the public of $16.00 per share, which includes 1,530,000 shares issued upon the e

GlobeNewswire 6 months ago

MBX
-8.61%
MBX Biosciences Announces Pricing of Initial Public Offering

CARMEL, Ind., Sept. 12, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX) (“MBX Biosciences”), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the pricing of its initial public offering of 10,200,000 shares of its common stock at a price to the public of $16.00 per share. The gross proceeds to MBX Biosciences from the offering, before deducti

GlobeNewswire 6 months ago

MBX
-8.61%
Will MBX Biosciences (NASDAQ:MBX) Spend Its Cash Wisely?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Simply Wall St. 6 months ago

MBX
-8.61%

Performance Overview

Return	MBX	S&P 500 (^GSPC)
YTD	-65.44%	-8.25%
1-Year	-72.30%	+3.55%
3-Year	-72.30%	+18.71%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Live

MBX Biosciences, Inc. (MBX)

MBX Biosciences to Participate in the 24th Annual Needham Virtual Healthcare Conference

MBX Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights

Insider Buyers At MBX Biosciences Likely Disappointed With 17% Slide

MBX Biosciences Announces Additions to Leadership Team

MBX Biosciences Completes Enrollment in Phase 2 Avail™ Trial of MBX 2109 (Canvuparatide) for Hypoparathyroidism

MBX Biosciences to Participate in March Investor Conferences

MBX Biosciences to Participate in Upcoming February Investor Conferences

MBX Biosciences' Investigational Drug For Weight Loss Surgery-Related Low Blood Sugar Shows Encouraging Action

MBX Biosciences Announces Positive Phase 1 Topline Results for MBX 1416 for the Treatment of Post-bariatric Hypoglycemia

MBX Biosciences to Participate in 43rd Annual J.P. Morgan Healthcare Conference

MBX Biosciences Announces MBX 2109 Phase 1 Study Results Published in The Journal of Clinical Endocrinology and Metabolism

MBX Biosciences Announces Last Subject Last Visit in Phase 1 Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia

MBX Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update

MBX Biosciences to Participate in Upcoming November Investor Conferences

Opening Day: Another trio of biotech IPOs make Friday debut

MBX Biosciences Presents MBX 2109 Phase 2 Avail™ Hypoparathyroidism Trial Rationale and Design at the ASBMR 2024 Annual Meeting

OrbiMed Advisors LLC Acquires New Stake in MBX Biosciences Inc

MBX Biosciences Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

MBX Biosciences Announces Pricing of Initial Public Offering

Will MBX Biosciences (NASDAQ:MBX) Spend Its Cash Wisely?

Performance Overview